| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 6183316 | Gynecologic Oncology | 2014 | 9 Pages |
•Oxysterols synergize with statins enhancing apoptosis in ovarian cancer cells.•SREBP-2 is a key regulator of statin response in ovarian cancer cells.•Ovarian cancer cells are sensitive to statins by at least two distinct mechanisms.
ObjectiveDetermine mechanisms responsible for enhanced statin efficacy in a novel statin combination we name STOX (STatin–OXysterol).MethodsOvarian cancer cell lines were treated with combinations of statins and oxysterols. Cell viability was determined by a modified MTT assay. Apoptosis was evaluated by immunoblotting of PARP and DAPI-mediated visualization of apoptotic nuclei. STOX effects on the expression of genes of the mevalonate pathway were assessed by real-time qPCR and immunoblotting. siRNA-mediated gene silencing was used to test the involvement of oxysterol-mediated repression of SREBP-2 in STOX synergy. The impact of statin-mediated inhibition of protein prenylation and on cholesterol homeostasis was evaluated.ResultsOxysterols dramatically enhance cytotoxicity of statins in ovarian cancer cells through increased apoptosis. Decreased expression of SREBP-2 down-regulates the mevalonate pathway and prevents the active statin-induced sterol feedback, enhancing statin toxicity. Comparison of two ovarian cancer cell lines reveals two distinct mechanisms of statin induced toxicity, namely, dependence on protein geranylgeranylation and/or perturbation of cellular cholesterol levels.ConclusionsWe provide evidence of statins' mechanisms of cytotoxicity in different ovarian cancer cells and discovered a new approach to significantly enhance the anti-tumor activity of statins. These observations provide a potential new path to improve statins as a treatment against ovarian cancer with obtainable dosages.
